(firstQuint)Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder.

 Eligible participants for this study must have a diagnosis of current IED.

 This is a multicenter, randomized, double-blind, placebo-controlled study, consisting of up to 12 weeks of treatment.

.

 Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder@highlight

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).

